phrykt

Teva Pharmaceutical Industries Ltd (TEVA): who owns it and who trades it

As of Nov 16, 2026, TEVA insiders reported 64 open-market sales worth $125M and no purchases in the last 12 months, with 8% of the sale value made under pre-set 10b5-1 plans. The largest seller was Richard D Francis (CEO), with $41.8M. 7 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling TEVA Pharmaceutical Industries

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TEVA

673 funds and institutions reported TEVA shares worth $26.1B at the end of Q2 2026, about 67% of the company. The largest holder is BlackRock, Inc. with 5.5%.

Funds and institutions (13F) 67%Everyone else 33%

10 largest owners, by share of the company

BlackRock, Inc.5.5%
Harel Insurance Investments & Financial Services Ltd.4.1%
California State Teachers Retirement System3.7%
Phoenix Financial Ltd.3.7%
Wcm Investment Management, LLC3.5%
Clal Insurance Enterprises Holdings Ltd3.5%
Menora Mivtachim Holdings Ltd.3.4%
Migdal Insurance & Financial Holdings Ltd.3.3%
Norges Bank2.8%
FMR LLC (Fidelity)2.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.63.89M5.48%$2.2B-2%
Harel Insurance Investments & Financial Services Ltd.48.14M4.13%$1.6B+5%
California State Teachers Retirement System43.27M3.71%$1.3B+3376%
Phoenix Financial Ltd.42.93M3.68%$1.5B+0%
Wcm Investment Management, LLC41.32M3.55%$1.4B+1%
Clal Insurance Enterprises Holdings Ltd40.60M3.48%$1.4B+6%
Menora Mivtachim Holdings Ltd.39.85M3.42%$1.4B+1%
Migdal Insurance & Financial Holdings Ltd.38.92M3.34%$1.3B+3%
Norges Bank32.30M2.77%$1.1B–
FMR LLC (Fidelity)30.26M2.60%$1B-9%
Lingotto Investment Management LLP20.21M1.73%$685M-27%
State Street Corp18.94M1.63%$642M+6%
Rubric Capital Management LP15.57M1.34%$528M+2%
Capital World Investors12.54M1.08%$425M+42%
Altshuler Shaham Ltd12.47M1.07%$412M+9%
Geode Capital Management, LLC11.61M1.00%$391M+10%
Meitav Investment House Ltd9.95M0.85%$337M–
Northern Trust Corp7.96M0.68%$270M+4%
Wellington Management Group LLP7.67M0.66%$260M+6%
JPMorgan Chase & Co6.98M0.60%$233M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TEVA insiders reported $0 of open-market purchases and $125M of sales. 8% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$125M
64 trades, 15 people
Sales under a 10b5-1 plan
8%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 12, 2026

Purchases and sales by month

$29.7M$29.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Mark SabagSee "Remarks"Sale44,710$44.14$2MForm 4
Nov 11, 2026Richard DaniellVice presidentSale20,003$42.80$856KForm 4
Nov 10, 2026Richard D FrancisCEOSale plan250,000$42.24$10.6MForm 4
Nov 9, 2026Richard DaniellVice presidentSale25,000$42.91$1.1MForm 4
Nov 9, 2026Amir WeissChief Accounting OfficerSale662$43.15$28.6KForm 4
Nov 9, 2026Amir WeissChief Accounting OfficerSale7,093$43.03$305KForm 4
Nov 9, 2026Amir WeissChief Accounting OfficerSale9,534$43.03$410KForm 4
Nov 5, 2026Mark SabagSee "Remarks"Sale46,000$41.93$1.9MForm 4
Nov 4, 2026Dov BergwerkInterim Cheif Legal OffiSale17,505$41.72$730KForm 4
Nov 4, 2026Dov BergwerkInterim Cheif Legal OffiSale8,755$41.72$365KForm 4
Sep 18, 2026Brian SavageInterim Chief Legal OffiSale314$38.70$12.2KForm 4
Sep 18, 2026Brian SavageInterim Chief Legal OffiSale2,525$39.15$98.9KForm 4
Sep 18, 2026Brian SavageInterim Chief Legal OffiSale4,503$38.69$174KForm 4
Sep 18, 2026Roberto MignoneDirectorSale367,600$39.06$14.4MForm 4
Aug 21, 2026Amir WeissChief Accounting OfficerSale2,500$37.63$94.1KForm 4
Aug 21, 2026Amir WeissChief Accounting OfficerSale6,945$37.61$261KForm 4
Aug 21, 2026Ronit Satchi-FainaroDirectorSale415$37.25$15.5KForm 4
Aug 17, 2026Evan LippmanVice presidentSale18,600$36.57$680KForm 4
Aug 5, 2026Tal Zvi ZaksDirectorSale17$34.87$593Form 4
Aug 3, 2026Placid JoverSee "Remarks"Sale12,827$34.88$447KForm 4
Aug 3, 2026Eric A HughesSee "Remarks"Sale25,578$34.88$892KForm 4
Jun 18, 2026Matthew ShieldsVice presidentSale9,989$32.19$322KForm 4
Jun 11, 2026Eliyahu Sharon KalifCFOSale106,563$34.10$3.6MForm 4
Jun 5, 2026Richard D FrancisCEOSale6,153$34.35$211KForm 4
Jun 3, 2026Matthew ShieldsVice presidentSale16,195$32.87$532KForm 4
May 14, 2026Evan LippmanVice presidentSale5,746$35.58$204KForm 4
May 14, 2026Evan LippmanVice presidentSale35,912$35.58$1.3MForm 4
May 14, 2026Eliyahu Sharon KalifCFOSale153,251$35.61$5.5MForm 4
May 6, 2026Amir WeissChief Accounting OfficerSale10,679$36.00$384KForm 4
May 5, 2026Richard DaniellVice presidentSale30,000$35.40$1.1MForm 4
May 1, 2026Mark SabagSee "Remarks"Sale144,180$34.99$5MForm 4
Apr 30, 2026Christine FoxVice presidentSale21,258$35.31$751KForm 4
Mar 17, 2026Mark SabagSee "Remarks"Sale62,102$30.14$1.9MForm 4
Mar 5, 2026Richard D FrancisCEOSale20,025$31.67$634KForm 4
Mar 5, 2026Christine FoxVice presidentSale7,924$31.67$251KForm 4
Mar 5, 2026Eric A HughesSee "Remarks"Sale9,533$31.67$302KForm 4
Mar 5, 2026Richard DaniellVice presidentSale17,295$31.67$548KForm 4
Mar 5, 2026Placid JoverSee "Remarks"Sale14,150$31.67$448KForm 4
Mar 5, 2026Brian SavageInterim Chief Legal OffiSale1,127$31.67$35.7KForm 4
Mar 4, 2026Richard D FrancisCEOSale23,393$32.46$759KForm 4
Mar 4, 2026Richard DaniellVice presidentSale33,512$32.46$1.1MForm 4
Mar 4, 2026Richard DaniellVice presidentSale37,372$32.95$1.2MForm 4
Mar 4, 2026Richard DaniellVice presidentSale20,461$32.46$664KForm 4
Mar 4, 2026Eric A HughesSee "Remarks"Sale11,277$32.46$366KForm 4
Mar 4, 2026Christine FoxVice presidentSale9,098$32.46$295KForm 4
Mar 4, 2026Brian SavageInterim Chief Legal OffiSale1,186$32.46$38.5KForm 4
Mar 4, 2026Brian SavageInterim Chief Legal OffiSale1,489$32.46$48.3KForm 4
Mar 3, 2026Richard DaniellVice presidentSale66,735$32.36$2.2MForm 4
Mar 3, 2026Richard DaniellVice presidentSale62,250$32.36$2MForm 4
Mar 3, 2026Brian SavageInterim Chief Legal OffiSale1,274$32.36$41.2KForm 4
Mar 3, 2026Richard D FrancisCEOSale30,903$32.36$1MForm 4
Mar 3, 2026Richard D FrancisCEOSale412,032$32.36$13.3MForm 4
Mar 3, 2026Eric A HughesSee "Remarks"Sale12,077$32.36$391KForm 4
Mar 3, 2026Eric A HughesSee "Remarks"Sale68,685$32.36$2.2MForm 4
Feb 26, 2026Eliyahu Sharon KalifCFOSale345,810$33.64$11.6MForm 4
Feb 15, 2026Richard D FrancisCEOSale161,656$34.22$5.5MForm 4
Feb 15, 2026Richard D FrancisCEOSale286,122$34.22$9.8MForm 4
Dec 16, 2025Amir WeissChief Accounting OfficerSale12,300$30.20$371KForm 4
Dec 16, 2025Roberto MignoneDirectorSale77,400$30.24$2.3MForm 4
Dec 9, 2025Richard DaniellVice presidentSale115,468$28.68$3.3MForm 4
Dec 9, 2025Mark SabagSee "Remarks"Sale98,168$28.70$2.8MForm 4
Dec 9, 2025Mark SabagSee "Remarks"Sale118,724$28.75$3.4MForm 4
Nov 26, 2025Roberto MignoneDirectorSale50,000$26.03$1.3MForm 4
Nov 20, 2025Christine FoxVice presidentSale28,229$24.78$700KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Richard D FrancisPresident and CEO–$41.8MNov 10, 2026
Eliyahu Sharon KalifEVP, Chief Financial Officer–$20.7MJun 11, 2026
Roberto MignoneDirector–$18MSep 18, 2026
Mark SabagSee "Remarks"–$17MNov 12, 2026
Richard DaniellExec. VP, European Commercial–$14MNov 11, 2026
Eric A HughesSee "Remarks"–$4.2MAug 3, 2026
Evan LippmanEVP, Business Development–$2.2MAug 17, 2026
Christine FoxEVP, Head of U.S. Commercial–$2MApr 30, 2026
Amir WeissChief Accounting Officer–$1.9MNov 9, 2026
Dov BergwerkInterim Cheif Legal Officer–$1.1MNov 4, 2026
Placid JoverSee "Remarks"–$896KAug 3, 2026
Matthew ShieldsEVP, Global Operations–$854KJun 18, 2026
Brian SavageInterim Chief Legal Officer–$449KSep 18, 2026
Ronit Satchi-FainaroDirector–$15.5KAug 21, 2026
Tal Zvi ZaksDirector–$593Aug 5, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TEVA short interest

Low short interest. 2.4% of TEVA shares are sold short: about 1 share in 42. Over the last 12 reports the number of shares short went up 4%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 27.74M TEVA shares were sold short, 2.4% of the shares outstanding, down 1.2% from the report before. At the average daily volume of 5.23M shares, buying them all back would take about 5.3 trading days (days to cover).

Shares short, % of all shares

2.38%May 15Oct 303.37%

Days to cover

5.3May 15Oct 3030.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202627.74M2.38%-1%5.23M5.3
Oct 15, 202628.07M2.41%-6%7.16M3.9
Sep 30, 202629.85M2.56%-5%5.53M5.4
Sep 15, 202631.48M2.70%+11467%1.15M27.4
Aug 31, 202637.61M3.23%+5%4.88M7.7
Aug 14, 202635.67M3.06%+4%5.38M6.6
Jul 31, 202634.32M2.95%+5%5.98M5.7
Jul 15, 202632.74M2.81%+2%5.03M6.5
Jun 30, 202632.03M2.75%-4%6.28M5.1
Jun 15, 202633.35M2.86%-2%6.15M5.4
May 29, 202633.87M2.91%+27%5.65M6.0
May 15, 202626.65M2.29%-14%6.68M4.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded TEVA

Since Nov 17, 2024, 1 member of Congress reported 1 purchase and 0 sales of TEVA. The latest was a purchase by Alan Armstrong on Mar 30, 2026, reported Jul 21, 2026.

Purchases 1Sales 0

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Mar 30, 2026Alan Armstrong (R-OK)Purchase$1K–$15KSelfJul 21, 2026Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

TEVA Pharmaceutical Industries company events

TEVA Pharmaceutical Industries filed 13 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Oct 29, 2026LeadershipAt a meeting of the Board of Directors of Teva Pharmaceutical Industries Ltd., the Board elected Dr. David J. Brailer to serve as a member of the Board, effective November 3, 2026, until Teva’s 2027 annual meeting of shareholders. Filing
  3. Sep 16, 2026Agreement(i) Teva Pharmaceutical Finance Netherlands II B.V., a wholly owned subsidiary of Teva Pharmaceutical Industries Limited, issued €1,000,000,000 of 4.250% Senior Notes due 2033 and €500,000,000 of 4.625% Senior Notes due 2036 (the “ 2036 Euro Notes ” and, together with the 2033 Euro Notes, the “… Filing
  4. Sep 14, 2026AnnouncementResults of Operations and Financial Condition. Filing
  5. Sep 11, 2026AnnouncementTeva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV” and together with Teva Finance II and Teva Finance III, the “Issuers”) and, the Company, as guarantor, entered into an underwriting… Filing
  6. Sep 3, 2026AnnouncementTeva Pharmaceutical Industries Limited is filing this Current Report on Form 8-K to recast historical segment information as set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 3, 2026. Filing
  7. Sep 3, 2026SharesChanged the rights of its shareholders. Filing
  8. Jul 29, 2026ResultsReleased financial results. Filing
  9. May 28, 2026VoteReported shareholder vote results. Filing
  10. Apr 29, 2026ResultsReleased financial results. Filing
  11. Jan 28, 2026ResultsReleased financial results. Filing
  12. Jan 12, 2026ResultsReleased financial results. Filing
  13. Dec 11, 2025AgreementTeva Pharmaceutical Industries Limited obtained the consent of each of the lenders party to its Revolving Facility Agreement (as defined below) to extend the stated maturity date of the commitments and loans thereunder from April 29, 2027 to April 29, 2028, and to amend certain terms of the… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

TEVA Pharmaceutical Industries financials

Famous investors that hold TEVA

7 of the 50 well-known investors we track reported holding TEVA in their latest 13F filing. The largest position is Larry Robbins's, worth $300M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Larry Robbins · Glenview Capital ManagementQ3 20267.57M$300M5.3%New
David Einhorn · Greenlight Capital (DME)Q3 20261.82M$72M2.0%New
Israel Englander · Millennium ManagementQ3 20261.47M$58M0.0%New
Ray Dalio · Bridgewater AssociatesQ3 2026982,873$38.9M0.2%New
Ken Griffin · Citadel AdvisorsQ3 2026766,167$30.3M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 2026440,000$17.4M0.1%New
Cathie Wood · ARK Investment ManagementQ3 202668,295$2.7M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named TEVA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Phoenix Financial Ltd.13G/A4.8%
Nov 16, 2026Phoenix Financial Ltd.13G/A4.8%
Nov 10, 2026MENORA MIVTACHIM HOLDINGS LTD.13G/A5.0%
Nov 10, 2026MENORA MIVTACHIM HOLDINGS LTD.13G/A5.0%
Nov 2, 2026Harel Insurance Investments & Financial Services Ltd.13G/A6.0%
Nov 2, 2026Harel Insurance Investments & Financial Services Ltd.13G/A6.0%

Questions about Teva Pharmaceutical Industries Ltd (TEVA) stock

Who owns the most TEVA stock?

The largest reported owner of Teva Pharmaceutical Industries Ltd (TEVA) is BlackRock, Inc., with 5.5% of the company. In total, 673 funds and institutions reported holding TEVA at the end of Q2 2026, together about 67% of the shares. See the largest owners.

Are TEVA insiders buying or selling?

In the last 12 months, TEVA insiders reported no open-market purchases and 64 sales worth $125M. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in TEVA?

As of Oct 30, 2026, 27.74M TEVA shares were sold short, 2.4% of the shares outstanding, down 1.2% from the report before. At the average daily volume of 5.23M shares, buying them all back would take about 5.3 trading days (days to cover). See the history.

Have members of Congress traded TEVA?

Yes. 1 member of Congress reported 1 purchase and 0 sales of TEVA since Nov 17, 2024. The latest was reported on Jul 21, 2026. See the trades.

Which famous investors hold TEVA?

7 of the 50 well-known investors we track reported TEVA in their latest 13F filing, including Larry Robbins, David Einhorn, Israel Englander. The largest position is worth $300M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.